An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ... Nature: One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio Milwaukee Journal Sentinel: PlacidWay Expands ITC Tijuana Partnership to Advance Natural Cancer and Chronic Disease Treatments PlacidWay Expands ITC Tijuana Partnership to Advance Natural Cancer and Chronic Disease Treatments Lupus Foundation of America: Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation – a breakthrough that could lead to new treatments for chronic diseases ... TEV '325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis WASHINGTON and NESS ZIONA, Israel, ...
